ArticleJournal of clinical microbiology2021
Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Antimicrobial Susceptibility Testing.
Article in Journal of clinical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Rapid MALDI-TOF MS antimicrobial susceptibility testing with the MBT FAST assay.Journal of clinical microbiology · 2026Article
- Rapid Detection of Carbapenemase-Producing Acinetobacter Baumannii Using MALDI-TOF Mass Spectrometry: A Technological Advancement in Clinical Microbiology.Iranian journal of biotechnology · 2026Article
- DOT-MGA for rapid determination of susceptibility to the combination of Ceftazidime-avibactam and Aztreonam among Enterobacterales.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Harnessing machine learning to predict antibiotic susceptibility in Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2025Article
- LC-MS/MS metabolomics unravels the resistant phenotype of carbapenemase-producing Enterobacterales.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Effect of host microenvironment and bacterial lifestyles on antimicrobial sensitivity and implications for susceptibility testing.npj antimicrobials and resistance · 2025Review
- MALDI-TOF MS in conjunction with machine learning: toward a new era for antimicrobial susceptibility testing.Frontiers in cellular and infection microbiology · 2025Review
- In-depth analysis of the treatment effect and synergistic mechanism of TanReQing injection on clinical multi-drug resistantMicrobiology spectrum · 2024Article
- Rapid Drug Susceptibility Testing to Preserve Antibiotics.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Mass spectrometry-based proteomics as an emerging tool in clinical laboratories.Clinical proteomics · 2023Review
- Evaluation of a Novel Benchtop Tool for Acceleration of Sample Preparation for MALDI-TOF Mass Spectrometry.Journal of clinical microbiology · 2023Article
- Direct Detection of Carbapenemase-Producing Klebsiella pneumoniae by MALDI-TOF Analysis of Full Spectra Applying Machine Learning.Journal of clinical microbiology · 2023Article
- Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism againstAntibiotics (Basel, Switzerland) · 2023Article
- Deep Learning and Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2022Review
- Evaluation of a rapid susceptibility test of polymyxin B by MALDI-TOF.Frontiers in microbiology · 2022Article
- Rapid Simultaneous Testing of Multiple Antibiotics by the MALDI-TOF MS Direct-on-Target Microdroplet Growth Assay.Diagnostics (Basel, Switzerland) · 2021Article
- Application and Perspectives of MALDI-TOF Mass Spectrometry in Clinical Microbiology Laboratories.Microorganisms · 2021Review
- Direct-on-Target Microdroplet Growth Assay for Detection of Bacterial Resistance in Positive Blood Cultures.Infection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) in clinical microbiology has dramatically improved the accuracy and speed of diagnostics. However, this progress has mainly been limited to the identification of microorganisms, whereas the practical improvement of antimicrobial susceptibility testing (AST) still lags behind. MALDI-TOF MS-based approaches include the detection of selected resistance mechanisms and the universal phenotypic AST. This minireview focuses on the discussion of those MALDI-TOF MS methods that allow universal growth-based phenotypic AST. The method of minimal profile change concentrations (MPCC) is based on detecting proteome modification in the presence of an antimicrobial. Using stable-isotope labeling, characteristic mass shifts in the presence of an antimicrobial indicate the incorporation of the isotopic labels, and thus the viability and resistance of the microorganism. For MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA), microorganisms are incubated with or without an antimicrobial, followed by cell lysis, protein extraction, and transfer of the cell lysate onto a MALDI target plate. Using the internal standard, peak intensities are correlated to the amount of microbial proteins, and the relative microbial growth is calculated. Most recent development in the field is the direct-on-target microdroplet growth assay (DOT-MGA). Here, incubation of microorganisms with antimicrobials takes place directly on spots of a MALDI target in the form of microdroplets. After incubation, nutrient medium is removed by dabbing with absorptive material. Resistant microorganisms grow despite the presence of antimicrobial, and their amplified biomass is detected by MALDI-TOF MS. Finally, an outlook is provided for further assay improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.